Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma

Oncotarget

Volumn 7, Issue 32, 2016, Pages 50875-50882

  Javier, Breanna M ^a   Yaeger, Rona ^a   Wang, Lu ^a   Sanchez Vega, Francisco ^a   Zehir, Ahmet ^a   Middha, Sumit ^a   Sadowska, Justyna ^a   Vakiani, Efsevia ^a   Shia, Jinru ^a   Klimstra, David ^a   Ladanyi, Marc ^a   Iacobuzio Donahue, Christine A ^a   Hechtman, Jaclyn F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal carcinoma; KRAS; Oncogene; Pathology Section; SOX9; TP53

Indexed keywords

APC PROTEIN; B RAF KINASE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR SOX9; KRAS PROTEIN, HUMAN; PROTEIN P21; SOX9 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; APC GENE; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CANCER PATIENT; CARCINOGENESIS; CLINICAL FEATURE; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PIK3CA GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STABILITY; SOMATIC MUTATION; SOX9 GENE; SPLICING DEFECT; SURVIVAL TIME; TP53 GENE; WILD TYPE; AGED; BIOSYNTHESIS; COLORECTAL TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION;

ADULT; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); SOX9 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84982311338     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9682     Document Type: Article

References (19)

1. Matsushita M, Kitoh H, Kaneko H, Mishima K, Kadono I, Ishiguro N, Nishimura G. A novel SOX9 H169Q mutation in a family with overlapping phenotype of mild campomelic dysplasia and small patella syndrome. Am J Med Genet. 2013; 161A: 2528-34. doi: 10.1002/ajmg.a.36134.
2. Mattos EP, Sanseverino MT, Magalhães JA, Leite JC, Félix TM, Todeschini LA, Cavalcanti DP, Schuler-Faccini L. Clinical and molecular characterization of a Brazilian cohort of campomelic dysplasia patients, and identification of seven new SOX9 mutations. Genet Mol Biol. 2015; 38: 14-20. doi: 10.1590/S1415-475738120140147.
3. Wang HY, Lian P, Zheng PS. SOX9, a potential tumor suppressor in cervical cancer, transactivates p21WAF1/ CIP1 and suppresses cervical tumor growth. Oncotarget. 2015; 6: 20711-22. doi: 10.18632/oncotarget.4133.
4. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene. 2004; 23: 4584-93. doi: 10.1038/sj.onc.1207603
5. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T, Bourgaux JF, Garambois V, Jay P, Blache P, Joubert D, Hollande F. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res. 2008; 68: 4258-68. doi: 10.1158/0008-5472.CAN-07-5805.
6. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, Skotheim RI, Lothe RA, López de Munain A, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012; 72: 1301-15. doi: 10.1158/0008-5472.CAN-11-3660.
7. Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q, Lai M. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008; 130: 897-904. doi: 10.1309/ AJCPW1W8GJBQGCNI.
8. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-7. doi: 10.1038/nature11252.
9. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O' Reilly C, Sadowska J, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capturebased next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015; 17: 251-64. doi: 10.1016/j.jmoldx.2014.12.006.
10. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, Wendl MC, Ding L. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014; 30:1015-6. doi: 10.1093/bioinformatics/btt755.
11. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-4. doi: 10.1158/2159-8290.CD-12-0095.
12. Thike AA, Chng MJ, Fook-Chong S, Tan PH. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001; 33: 21-5. doi: 10.1080/00313020123290
13. Neu-Yilik G, Amthor B, Gehring NH, Bahri S, Paidassi H, Hentze MW, Kulozik AE. Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. RNA. 2011; 17: 843-54. doi: 10.1261/rna.2401811.
14. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, Dietz HC. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science. 2002; 295: 2258-61. doi: 10.1126/science.1067338.
15. Abdel-Samad R, Zalzali H, Rammah C, Giraud J, Naudin C, Dupasquier S, Poulat F, Boizet-Bonhoure B, Lumbroso S, Mouzat K, Bonnans C, Pignodel C, Raynaud P, et al. MiniSOX9, a dominant-negative variant in colon cancer cells. Oncogene. 2011; 30: 2493-503. doi: 10.1038/ onc.2010.621.
16. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004; 166: 37-47. doi: 10.1083/jcb.200311021.
17. Jay P, Berta P, Blache P. Expression of the carcinoembryonic antigen gene is inhibited by SOX9 in human colon carcinoma cells. Cancer Res. 2005; 65: 2193-8 doi: 10.1158/0008-5472.CAN-04-1484.
18. Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C, Bibeau F, Scherer G, Joubert D, Hollande F, Blache P, Jay P. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol. 2007; 178: 635-48. doi: 10.1083/ jcb.200704152
19. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-57.